REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. COLLABORATION AND LICENSE AGREEMENT dated byCollaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”) and is entered into by and between:
FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT Dated 19 December 2019 BETWEEN GENMAB B.V. AND CUREVAC AGCollaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT ("First Amendment") is made the 2nd day of July 2020 ("First Amendment Effective Date"), by and between:
Global Access Commitments AgreementGlobal Access Commitments Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations • New York
This Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the “Agreement”), is entered into as of February 13, 2015 (“Effective Date”), by and between the Bill & Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the “Foundation”), and CureVac GmbH, a German limited company, together with its Affiliates (“CureVac” or the “Company”), in connection with the Foundation making a program-related investment in the Company by acquiring Series B Shares of the Company issued from the Company as part of one or more capital increases (the “Shares”) (the acquisition of Shares is referred to herein as the “Foundation Investment”). The Foundation Investment is subject to the terms and conditions of the investment documents executed in connection with the closing (“Closing”), including, without limitation, this Agreement, and the Investment and Shareholders’ Agreement (the “Shareholders’ Agreement”) among the Com
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. DATED: 15 February 2019 FRAMEWORK PARTNERING...Framework Partnering Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations • England and Wales
ContractSupplement to the Rental Contract • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
Dated 17 July 2020 KFW and DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG and CUREVAC B.V. (to be converted into CUREVAC N.V.) RELATIONSHIP AGREEMENTRelationship Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
The Co-Shareholders and the Company may each be referred to herein individually as a “Party” and collectively as the “Parties”.
Agreement betweenVap Contract • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
The BENEFICIARY has concluded a contract with the legal predecessor of CUREVAC, CureVac GmbH, on […] [and where applicable on […]] to participate in the employee participation pro-gram (hereinafter referred to as “VAP”; the above jointly (including all supplements) referred to as “VAP CONTRACT”). The VAP contract has gaps and inaccuracies that are now to be filled or specified.
REDACTED Certain identified information, indicated by [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. YALE UNIVERSITY COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations • Connecticut
This is a RESEARCH AGREEMENT (the “Agreement”) effective July 1st, 2019, (the “Effective Date”) by and between YALE UNIVERSITY, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”) and Cure Vac AG, a German stock corporation, having its principal offices at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (the “Sponsor”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. DEVELOPMENT AND INTELLECTUAL PROPERTY AGREEMENTDevelopment and Intellectual Property Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
THIS DEVELOPMENT AND INTELLECTUAL PROPERTY AGREEMENT (the “Agreement”) is effective as of November 24, 2015 (the “Effective Date”), by and between TESLA GROHMANN AUTOMATION GMBH, a company established under the laws of Germany with offices at Rudolf-Diesel-Straße 14, 54595 Prüm (“TGA”), and CUREVAC AG, a German stock corporation with its principal place of business located at Paul-Ehrlich-Straße 15, 72076 Tübingen, Germany (“CureVac”). CureVac and TGA are each referred to herein as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 3 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTExclusive Collaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
WHEREAS, the Parties entered into that certain Exclusive Collaboration and License Agreement effective as of August 21, 2014 (the "Original Agreement"), as amended by the first amendment effective as of June 30, 2015 (the "Amendment No. 1") and by the second amendment effective as of August 1, 2016 (the "Amendment No. 2") (the Original Agreement, as amended by Amendment No. 1 and Amendment No. 2, the "Agreement");
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Amendment Two to Development and Option AgreementDevelopment and Option Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This Amendment Two to the Development and Option Agreement (this "Amendment"), dated as of July 10, 2020 (the "Amendment Two Effective Date"), is made by and between CureVac AG, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tubingen, Germany ("CureVac"), and Acuitas Therapeutics Inc., a British Columbia corporation ("Acuitas") and amends and restates the Development and Option Agreement dated April 29, 2016 (as amended by the Side Agreement and Amendment Number One dated December 1,2016) between CureVac and Acuitas (the "Development and Option Agreement"). Each of CureVac and Acuitas may be referred to herein as a "Party" or together as the "Parties."
ContractRental Contract • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
This document is an English translation of a document prepared in German. In case of any ambiguity, the German text shall prevail.
AMENDMENT NO. 2 TO THE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENTExclusive Collaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
CureVac AG (formerly CureVac GmbH), a German limited liability company with offices at Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany ("CureVac"), and
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations • Massachusetts
This Sponsored Research Agreement (“Agreement”) is made as of the 15TH day of March 2019, (“Effective Date”), between Cure Vac AG, a German stock corporation, having a principal place of business at Paul-Ehrlich-Strasse 15, 72076 Tubingen, Germany (“Sponsor”) and The Schepens Eye Research Institute, Inc., (“SERI”) a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford St., Boston, MA 02114 and the Massachusetts Eye and Ear Infirmary (“MEET’) having a principal place of business at 243 Charles Street, Boston, MA 02114 (SERI and MEEI collectively “Institute”), each referred to herein individually as a “Party” and collectively as the “Parties.”
REDACTED Certain identified information, indicated by [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. 1st AMENDMENT TO THE SPONSORED RESEARCH AGREEMENT...Sponsored Research Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
WHEREAS, the Parties wish to extend the Term and include an updated Research Plan in the Agreement, the Parties intend to amend the Agreement; and
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Collaboration and LICENSE Agreement dated by and...Collaboration and License Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations
NOW THEREFORE, in consideration of the foregoing premises and the following mutual covenants and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
Definitive Agreement and Project Collaboration Plan for Assessment of RNA Vaccine Technology for Non-live Rotavirus Vaccines in Pre-clinical ModelsProject Agreement • July 24th, 2020 • CureVac B.V. • Pharmaceutical preparations • Washington
· CUREVAC and the Foundation have entered into a Framework Agreement for Cooperation having an effective date of December 11 2013 (“Framework Agreement”);
